Journal Article (Letter)

DKFZ-2024-02389

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.

Mai, E. K. ; Nogai, A. ; Lokhorst, H. M. ; van der Holt, B. ; Zweegman, S. ; Weisel, K. C. ; Croockewit, S. ; Jauch, A. ; Hillengass, J. ; Stevens-Kroef, M. ; Raab, M. S. ; Broijl, A. ; Bos, G. M. J. ; Brossart, P. ; Ypma, P. ; Hanoun, C. ; Bertsch, U. ; Hielscher, T.DKFZ* ; Salwender, H. J. ; Scheid, C. ; Goldschmidt, H. ; Sonneveld, P.

2024
Wolters Kluwer Health [Philadelphia, Pennsylvania]

This record in other databases:  

Please use a persistent id in citations: doi:10.1002/hem3.70052

---

Contributing Institute(s):

1. C060 Biostatistik (C060)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---